• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical investigation >Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
【24h】

Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder

机译：经皮睾丸激素治疗性欲减退的安全性和有效性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hypoactive sexual desire disorder is a significant life-stressor prevalent among women of all ages worldwide. Androgens have been shown to maintain healthy female sexual function and testosterone supplementation has been used as an off-label treatment modality in the USA via oral, intramuscular, pellet or transdermal routes of delivery. It is hypothesized that transdermal testosterone delivery may be safer than other regimens because it bypasses first-pass hepatic metabolism. This article examines the current research on efficacy and safety of transdermal testosterone for the treatment of hypoactive sexual desire disorder. Although multiple randomized-controlled clinical trials have demonstrated that transdermal testosterone improves female sexual function with minimal side effects, long-term safety data is still needed, specifically to elucidate the possible long-term risks of breast cancer and cardiovascular disease.
机译：性冲动性欲障碍是全世界所有年龄段女性中普遍存在的重要生活压力源。雄激素已被证明可以维持健康的女性性功能，在美国，通过口服，肌肉内，颗粒或透皮给药途径，睾丸激素补充剂已被用作标签外治疗方式。据推测，经皮睾丸激素输送可能比其他方案更安全，因为它绕过了肝脏的首过代谢。本文探讨了经皮睾丸激素治疗性欲减退的有效性和安全性的最新研究。尽管多项随机对照临床试验表明，经皮睾丸激素可改善女性性功能，且副作用极小，但仍需要长期安全性数据，特别是阐明乳腺癌和心血管疾病的长期风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号